Search Results - "Yang, Nong"

Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients by Yang, Zhe, Yang, Nong, Ou, Qiuxiang, Xiang, Yi, Jiang, Tao, Wu, Xue, Bao, Hua, Tong, Xiaoling, Wang, Xiaonan, Shao, Yang W, Liu, Yunpeng, Wang, Yan, Zhou, Caicun

“…The third-generation tyrosine kinase inhibitor osimertinib is approved to treat patients with T790M-positive non-small cell lung cancer (NSCLC) who have…”
Get full text

GOPC-ROS1 Rearrangement as an Acquired Resistance Mechanism to Osimertinib and Responding to Crizotinib Combined Treatments in Lung Adenocarcinoma by Zeng, Liang, Yang, Nong, Zhang, Yongchang

Get more information

Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1 by Ye, Youqiong, Kuang, Xinwei, Xie, Zuozhong, Liang, Long, Zhang, Zhao, Zhang, Yongchang, Ma, Fangyu, Gao, Qian, Chang, Ruimin, Lee, Heng-Huan, Zhao, Shuang, Su, Juan, Li, Hui, Peng, Jingbo, Chen, Huifang, Yin, Minzhu, Peng, Cong, Yang, Nong, Wang, Jing, Liu, Jing, Liu, Hong, Han, Leng, Chen, Xiang

“…Immune checkpoint blockade (ICB) therapy has demonstrated considerable clinical benefit in several malignancies, but has shown favorable response in only a…”
Get full text

The clinicopathologic of pulmonary adenocarcinoma transformation to small cell lung cancer by Yang, Haiyan, Liu, Li, Zhou, Chunhua, Xiong, Yi, Hu, Yijuan, Yang, Nong, Qu, Jingjing

“…Transformation to small cell lung cancer (SCLC) is one of the mechanisms of resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors…”
Get full text

Changes of tumor microenvironment in non-small cell lung cancer after TKI treatments by Chen, Shanshan, Tang, Jingyi, Liu, Fen, Li, Wei, Yan, Ting, Shangguan, Dangang, Yang, Nong, Liao, Dehua

“…Non-small cell lung cancer (NSCLC) is the most common lung cancer diagnosis, among which epidermal growth factor receptor (EGFR), Kirsten rat sarcoma (KRAS),…”
Get full text

Clinical impact of uncommon epidermal growth factor receptor exon 19 insertion-deletion variants on epidermal growth factor receptor-tyrosine kinase inhibitor efficacy in non-small-cell lung cancer by Peng, Xingzhou, Long, Xiaoyan, Liu, Li, Zeng, Liang, Yang, Haiyan, Jiang, Wenjuan, Liao, Dehua, Li, Kunyan, Wang, Jing, Lizaso, Analyn, Mao, Xinru, Xu, Qinqin, Mansfield, Aaron S., Yang, Nong, Zhang, Yongchang

“…Our study aimed to evaluate the efficacy and resistance mechanisms of first-line epidermal growth factor receptor (EGFR) inhibitor therapy in patients with…”
Get full text

The characteristics of ctDNA reveal the high complexity in matching the corresponding tumor tissues by Yang, Nong, Li, Yi, Liu, Zhidong, Qin, Hao, Du, Duanming, Cao, Xinkai, Cao, Xiaoqing, Li, Jun, Li, Dongge, Jiang, Bo, Duan, Lincan, Yang, Haiyan, Zhang, Zhenghua, Lin, Hao, Li, Jianying, Yang, Zhenhua, Xiong, Lei, Shen, Hua, Lin, Lizhu, Li, Fugen

“…Next-generation sequencing (NGS) is an efficient and sensitive method to detect mutations from ctDNA. Many features and clinical conditions could significantly…”
Get full text

Adaptive tracking control for a class of nonlinear non-strict-feedback systems by Li, Qiu-Ni, Yang, Ren-Nong, Liu, Zong-Cheng

“…This paper focuses on the adaptive tracking control problem for a class of nonlinear non-strict-feedback systems. By introducing a compact set, the restrictive…”
Get full text

Clinical outcomes for immune checkpoint inhibitors plus chemotherapy in non-small-cell lung cancer patients with uncommon driver gene alterations by Qin, Haoyue, Yan, Huan, Chen, Yangqian, Xu, Qinqin, Huang, Zhe, Jiang, Wenjuan, Wang, Zhan, Deng, Li, Zhang, Xing, Zhang, Lin, Yang, Nong, Zeng, Liang, Zhang, Yongchang

“…Limited data exists on the efficacy of immune checkpoint inhibitor (ICI) combinations in non-small-cell lung cancer (NSCLC) with uncommon driver alterations in…”
Get full text

Clinical activity of pembrolizumab with or without chemotherapy in advanced pulmonary large-cell and large-cell neuroendocrine carcinomas: a multicenter retrospective cohort study by Song, Lianxi, Zhou, Fei, Xu, Tian, Zeng, Liang, Xia, Qing, Wang, Zhan, Deng, Li, Li, Yizhi, Qin, Haoyue, Yan, Huan, Huang, Zhe, Mi, Jinye, Xu, Qinqin, Yang, Nong, Zhou, Caicun, Zhang, Yongchang

“…Immune checkpoint inhibitors (ICI)-based combination strategies have improved the survival outcomes in advanced non-small cell lung cancers; however, data…”
Get full text

Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study by Zhang, Yongchang, Zhang, Xiangyu, Zhang, Ruiguang, Xu, Qinqin, Yang, Haiyan, Lizaso, Analyn, Xu, Chunwei, Liu, Jun, Wang, Wenxian, Ou, Sai-Hong Ignatius, Zhang, Jiexia, Song, Zhengbo, Yang, Nong

“…Abstract Background ROS1 -rearranged lung cancers benefit from first-line crizotinib therapy; however, clinical and molecular factors that could affect…”
Get full text

Recent Advancements of Monotherapy, Combination, and Sequential Treatment of EGFR/ALK-TKIs and ICIs in Non–Small Cell Lung Cancer by Liao, Dehua, Yu, Lun, Shangguan, Dangang, Zhang, Yongchang, Xiao, Bowen, Liu, Ni, Yang, Nong

“…Lung cancer is the leading cause of cancer-related deaths with high morbidity and mortality. Non–small cell lung cancer (NSCLC) is the most common type of lung…”
Get full text

Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study by Zhang, Yongchang, Song, Lianxi, Zeng, Liang, Xiong, Yi, Liu, Li, Zhou, Chunhua, Yang, Haiyan, Wang, Zhan, Xia, Qing, Jiang, Wenjuan, Xu, Qinqin, Yang, Nong

“…Single-agent immunotherapy is currently the recommended second-line therapy for patients with advanced non-small cell lung cancer (NSCLC) without targetable…”
Get full text

Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC by Zhang, Yongchang, Zeng, Liang, Zhang, Xiangyu, Li, Yizhi, Liu, Lingli, Xu, Qinqin, Yang, Haiyan, Jiang, Wenjuan, Lizaso, Analyn, Qiu, Luting, Hou, Ting, Liu, Jun, Peng, Ling, Yang, Nong

“…Abstract Background The combination of bevacizumab and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) could prolong progression-free…”
Get full text

Alterations of the Human Lung and Gut Microbiomes in Non-Small Cell Lung Carcinomas and Distant Metastasis by Lu, Hui, Gao, Na L, Tong, Fan, Wang, Jiaojiao, Li, Huanhuan, Zhang, Ruiguang, Ma, Hong, Yang, Nong, Zhang, Yongchang, Wang, Ye, Liang, Zhiwen, Zeng, Hao, Chen, Wei-Hua, Dong, Xiaorong

“…Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths worldwide. Although dysbiosis of the lung and gut microbiota have been…”
Get full text

Genomic alterations associated with pseudoprogression and hyperprogressive disease during anti-PD1 treatment for advanced non-small-cell lung cancer by Zhou, Rui, Tong, Fan, Zhang, Yongchang, Zhang, Ruigang, Bin, Yawen, Zhang, Sheng, Yang, Nong, Dong, Xiaorong

“…Introduction This study aimed to elucidate the relationship between dynamic genomic mutation alteration and pseudoprogression (PsPD)/hyperprogressive disease…”
Get full text

Lipid alterations play a role in the integration of PD-1/PD-L1 inhibitors and anlotinib for the treatment of advanced non-small-cell lung cancer by Liu, Li, Zhang, Shuo, Yang, Hai-Yan, Zhou, Chun-Hua, Xiong, Yi, Yang, Nong, Tian, Ye

“…Studies have shown that integrating anlotinib with programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors enhances survival rates among…”
Get full text

Hypofractionated radiotherapy with immunochemotherapy for extensive-stage small-cell lung cancer by Liu, Chaoyuan, Zeng, Liang, Deng, Chao, Jiang, Wenjuan, Wang, Yapeng, Zhou, Yiguang, Liu, Li, Wang, Sisi, Zhou, Chunhua, Qiu, Zhenhua, Zeng, Fanxu, Wu, Fang, Weng, Jie, Liu, Xianling, Yang, Nong, Ma, Fang

“…The combination of a PD-L1 inhibitor plus carboplatin/cisplatin and etoposide (EC/EP) has become a new standard first-line treatment for extensive-stage…”
Get full text

Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study by Liu, Li, Kalyani, Farhin Shaheed, Yang, Haiyan, Zhou, Chunhua, Xiong, Yi, Zhu, Songlin, Yang, Nong, Qu, Jingjing

“…MET amplification or METex14 skipping mutations are uncommon oncogenic events in NSCLC patients. Clinicopathological characteristics, concurrent gene…”
Get full text

Flavonoids from the fruits of Phyllanthus acidus (L.) Skeels with anti-α-glucosidase activity by Xu, Jia, Xin, Ying, Zhu, Hong-Tao, Kong, Qing-Hua, Yang, Wei-Nong, Wang, Dong, Yang, Chong-Ren, Zhang, Ying-Jun

“…Eleven flavonoids including one new flavonol glycoside, quercetin-3-O-(2-α-L-rhamnopyranosyl)-β-D-glucuronopyranosyl methyl ester (1), were isolated for the…”
Get full text